The DNA-based Lassa vaccine INO-4500 confers durable protective efficacy in cynomolgus macaques against lethal Lassa fever.

ABSTRACT:

Background

We have previously developed a DNA-based vaccine, INO-4500, encoding the Lassa lineage IV glycoprotein precursor. INO-4500, when delivered with electroporation, elicited humoral and cellular responses, and conferred 100% protection in cynomolgus non-human primates. Here, we expanded the characterization of INO-4500 assessing immunogenicity and protective efficacy of lower doses and single immunization, and the durability of immune responses.

Methods

The study was divided into three arms evaluating INO-4500 vaccination: Arm 1 - Dosing regimen; Arm 2 - Single immunization; and Arm 3-Durability of immune responses and protective efficacy. Humoral and T cell responses were assessed by IgG binding ELISA, IFNγ ELISpot and flow cytometry-based T cell activation assays. N

SUBMITTER: Andrade VM 

PROVIDER: S-EPMC11605062 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature